Modulation of nuclear factor erythroid 2-related factor(Nrf2) and Kelch-like-ECH-associated protein 1 (KEAP1) has been identified as an attractive therapeutic strategy for interfering with oxidative stress-related diseases such as cancer, neurodegenerative, cardiovascular, metabolic, or inflammatory diseases [25]. This evidence concerns the gene KEAP1 and cancer.